Trial · NCT02249247
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
NCT02249247, Phase 2, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease. Trials, record NCT02249247. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02249247
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
- NCT number
- NCT02249247
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 577 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets, Placebo
- First posted
- 2014-09-25
- Last updated
- 2014-09-26
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in exercise endurance | Pre-dose, up to 12 weeks after start of treatment | evaluated by constant work load test |
| Secondary | Changes in breathlessness during constant work load test | Week 4 and week 12 weeks after start of treatment | measured by Modified Borg scale: Dyspnea score, leg discomfort |
| Secondary | Changes in forced expiratory volume in one second (FEV1) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in forced vital capacity (FVC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in forced expiratory flow at 25%-75% of FVC (FEF25-75%) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in inspiratory capacity (IC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Changes in slow vital capacity (SVC) | Pre-dose, up to 12 weeks after start of treatment | assessed by spirometry |
| Secondary | Change in thoracic gas volume | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in total lung capacity | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
| Secondary | Changes in residual volume | Pre-dose, up to 12 weeks after start of treatment | assessed by body plethysmography |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02249247
GET https://conductscience.org/api/trials/v1/NCT02249247/registered?page=2